SLN - Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results
2024-06-21 14:31:06 ET
Summary
- Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024.
- The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034.
- Positive results achieved in the phase 2 ALPACAR-360 study using zerlasiran for patients with elevated levels of Lp[a] at high risk of ASCVD.
- Full detailed results of phase 2 ALPACAR-360 study for zerlasiran are expected to be presented at an upcoming medical conference in 2024.
Silence Therapeutics plc ( SLN ) had recently reported positive results from its phase 2 ALPACAR-360 study using its drug zerlasiran [SLN360] for the treatment of patients who are at risk of atherosclerotic cardiovascular disease [ASCVD]. This was positive 48-week data, and the company had previously reported that patients who took this drug achieved a significant and sustained reductions of Lp[a] at week 36. As far as a catalyst opportunity goes for this program, additional completed results from this phase 2 ALPACAR-360 study will be presented at an upcoming medical meeting in 2024....
Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results